Signal from the log
Leal Therapeutics
30 M$ · Series A · United States · Biotech
Leal Therapeutics développe LTX-001, un candidat contre la schizophrénie qui entre en essai de phase 1b/2a. Extension de série A de 30 M$, second closing sans chef de file annoncé.
Verified
Announced on , logged by the watch of 17 August 2026.
- Operation
- Funding round
- Announced amount
- 30 M$
- Stage
- Series A
- Country
- United States
- Sector
- Biotech
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
With Eli Lilly and Company , OrbiMed , Newpath Partners , Euclidean Capital , SV Health Investors Dementia Discovery Fund , Chugai Venture Fund , Alexandria Venture Investments , PhiFund
Provenance
Source prnewswire,pulse2
Logged on 17 August 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.